DECREASE
12 Apr 2022
Trial Summary
Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that >90% of patients have disease apparent when using PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.
Acronym:
DECREASE
ACTRN/NCT /ethics:
NCT04319783
Scientific title:
DECREASE: Phase II DarolutamidE + Consolidation RadiothErapy in Advanced proStatE cancer detected by PSMA
Sponsor / Cooperative group:
Trans Tasman Radiation Oncology Group (TROG)
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Male |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2021-06-02 |
| Anticipated End Date | 2026-06-01 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Dr Braden Higgs |
| Recruitment Status | Recruiting |